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Abstract
Background: The combination of partial liver resection and radiofrequency ablation (RFA) is a
novel concept in the treatment of unresectable liver malignancies. The aim of this study is to
evaluate the results of this combined strategy in the Netherlands.
Methods: Thirty-five patients treated with a combination of partial liver resection and RFA were
identified from a prospectively registered pooled multicentre database. All patients were operated
between June 1999 and November 2003 in 8 medical centres in the Netherlands. Main outcome
parameters were morbidity, mortality, local success rate, and survival.
Results: Thirty-seven operations were performed in 35 patients. The group consisted of 20 male
and 15 female patients with a median age of 59 years (range 41–76). Seventy-six lesions were
resected and RFA was performed to ablate 82 unresectable liver tumours. Twelve patients
developed a total of 24 complications, resulting in an overall perioperative morbidity rate of 32%.
In two patients major complications resulted in postoperative death (postoperative mortality rate
5.4%). Local success rate after RFA was 88% and the estimated 1-, 2- and 3-year overall survival
rates were 84%, 70% and 43%, respectively.
Conclusion: This strategy should only be performed following strict patient selection and within
the context of prospective clinical trials.
Background
Partial liver resection is a well established treatment for
primary and secondary malignancies of the liver [1,2]. In
a selected population this is the sole potentially curative
treatment and is associated with reported 5-year survival
rates between 18 and 38% [3-5]. However, the great
majority of patients are not amenable to partial liver resec-
tion. Reasons to exclude patients for resection are extrahe-
patic disease, tumour location, inadequate functional
hepatic reserve or proximity to major vascular structures.
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World Journal of Surgical Oncology 2006, 4:46 http://www.wjso.com/content/4/1/46In recent years, locally ablative therapies have been used
as an alternative treatment for unresectable liver tumours.
The most widely used technique is radiofrequency abla-
tion (RFA). With this method a radiofrequent current is
applied through a needle electrode inserted directly into
the tumour, with the aim of destroying all malignant cells.
This technique is considered safe and efficient [6,7]. RFA
is a low risk procedure, with mortality rates of about 0.5
% and complication rates between 6.9 and 9.8 % [8-11].
However, especially following percutaneous RFA, local
recurrence rates up to 40% are reported in large series [12-
14]. Tumour recurrences at other sites are common (28–
70%), probably caused by negative patient selection
[12,13,15]. The overall outcome after RFA is difficult to
interpret, since results vary widely and follow up data are
immature.
Partial liver resection combined with RFA is a novel
approach used in patients with otherwise unresectable
lesions. Following resection, the remaining unresectable
liver tumours can be ablated, while preserving adequate
hepatic reserve. Although RFA has not yet proven to be
potentially curative, more patients become candidates for
surgical treatment by combining techniques with the pur-
pose of complete clearance of intrahepatic tumour.
The objective of this study was to determine the results of
hepatic resection combined with RFA in the Netherlands
with emphasis on perioperative morbidity and mortality,
recurrence rates and survival. The results were compared
with those reported in the literature.
Methods
Patients were selected from our prospectively recorded
multicentre database. Thirty-five patients were identified
who had been treated with a combination of partial liver
resection and RFA. All patients were operated between
June 1999 and November 2003 in 8 medical centres in the
Netherlands.
Preoperative work up consisted of a baseline history and
physical examination, serum laboratory tests, chest radio-
graph or chest computed tomography (CT) when indi-
cated, liver ultrasonography (US) or abdominopelvic
imaging with CT, magnetic resonance imaging (MRI) or
positron emission tomography (PET). The volume of the
remnant liver was assessed preoperatively. At least 30–
35% of functional liver parenchyma should be preserved.
Patients were considered unresectable based on advanced
bilobar tumour distribution, inadequate functional
hepatic reserve or proximity to major vascular structures.
In all patients complete tumour clearance was not possi-
ble without the addition of RFA.
All patients underwent partial liver resection and RFA dur-
ing laparotomy by an experienced liver surgeon. Intraop-
erative US was performed prior to the resection and RFA
to document and target the lesions. During RFA, US was
used to guide placement of the RF needle into the lesion
and to monitor the effect of the treatment. Routinely,
ultrasonic dissection technique was used to perform par-
tial liver resection. Three different RF systems were used in
the 8 medical centres (Radionics, Radiotherapeutics and
RITA Medical Systems, respectively). Specific RFA proto-
cols, designed by each of the three manufacturers, were
used for each system according to manufacturer recom-
mendations. A safety margin of 0.5–1.0 cm was aimed for
in surgery as well as in RFA.
Medical records were reviewed for demographics, prior
treatment, co-morbidity, tumour histology, number, size
and distribution of tumours, type and extent of resection,
application of Pringle manoeuvre, operative blood loss
and length of hospital stay. Co-morbidity was defined as
disease associated with an increased risk for operative
complications.
Main outcome parameters were morbidity, mortality,
recurrence and survival. Complications were considered
major, when 1) life threatening if left untreated, 2) lead-
ing to substantial disability, or 3) resulting in hospital
readmission or substantially lengthened hospital stay
[16]. All other complications were considered minor. All
complications following a procedure were registered.
When complications were clearly caused exclusively by
the ablation procedure they were considered RFA-related.
Liver failure was defined as a progressive increase of serum
bilirubin and the prothrombin time [17]. Postoperative
mortality was defined as in-hospital mortality. Follow up
was obtained by multiphasic CT or MRI at 3–4 month
intervals following therapy. Recurrence was defined as
newly developed tumours in untreated liver segments.
Local tumour progression was defined as progression of
residual unablated tumour or recurrence of tumour in the
RFA lesion. Survival was estimated using Kaplan-Meier
analysis.
Results
Thirty-seven operations were performed in 35 patients.
The group consisted of 20 male and 15 female patients
with a median age of 59 years (range 41–76).
The indication for treatment was colorectal metastases in
27 patients (77%), other liver metastases in 6 and hepato-
cellular carcinoma (HCC) in 2 patients (table 1). The
main indications for RFA was tumour proximity to major
vascular structures and bilobular distribution (table 2).
Nine patients had been treated for disseminated disease
prior to the combined partial liver resection and RFA. SixPage 2 of 6
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had previously undergone partial liver resection, one RFA
and one chemotherapy via hepatic artery infusion. Thir-
teen patients (37%) were known to have relevant co-mor-
bidity, including severe pulmonary and cardiac disorders,
cirrhosis and diabetes mellitus. Co-morbidity was not
associated with increased postoperative morbidity or
mortality. Most patients were evaluated by preoperative
multiphasic CT (n = 34), but also by MRI (n = 5) and PET
scanning (n = 1). All but one patient were operated with
curative intent, but none could be treated with partial liver
resection alone to remove all lesions while leaving suffi-
cient vital hepatic parenchyma.
One hundred fifty-eight primary and metastatic liver
tumours were treated by either partial liver resection or
RFA. Seventy-six lesions were resected with a mean (± SD)
of 2.1 ± 1.8 lesions per patient per laparotomy (range 1–
9). Seven patients (19%) underwent a major resection
(table 3). RFA was performed to ablate 82 unresectable
liver tumours, with a mean of 2.2 ± 1.5 lesions per patient
per laparotomy (range 1–7), and the median diameter of
the treated lesions was 19 mm (range 5–50 mm). The
Pringle manoeuvre was used in 4 patients. These were all
cases in which a tumour was located near major vessels
and vascular occlusion was used to reduce the heat sink
effect. Median blood loss was 550 ml (range 150–3500).
Median operating time was 240 minutes (range 120–
600).
Median hospital stay was 8 days (range 4–25). Twelve
patients developed a total of 24 complications, resulting
in an overall perioperative morbidity rate of 32%. Minor
complications included respiratory tract infection, pleural
effusion, thrombosis, cholangitis, urinary tract infection
and wound infection (table 4). Fourteen complications in
6 patients were considered major (major complication
rate 16%), including liver failure, biliary stricture, hepatic
abscess, necrotizing pancreatitis, peritonitis, postopera-
tive haemorrhage and pulmonary embolus. Seven com-
plications in 6 patients were considered solely RFA-related
(RFA-related morbidity 16%), including biliary stricture,
hepatic abscess and vascular damage. Three patients
developed biliary stricture following local ablation. In 1
patient a metastasis treated by RFA was located in segment
VIII, in the other 2 patients colorectal metastases in seg-
ment IV were treated by local ablation. In all 3 patients
local ablation was performed centrally in the liver, result-
ing in a stricture of the left or right hepatic duct. These
patients developed jaundice with peak bilirubin levels
ranging from 74 to 940 μmol/L. In all of these cases one
or more ERCP procedures were performed for stenting of
the biliary tract. Three patients developed hepatic
abscesses, 2 of which were located at the site of ablation
and, thus considered RFA-related. Treatment consisted of
percutaneous drainage (n = 1) or drainage via laparotomy
(n = 2). In one patient right portal vein thrombosis near
the RFA lesion was diagnosed during analysis for severe
ascites. In a second patient minor haemorrhage was
observed near the RFA-lesion as result of hepatic artery
damage (table 4).
In two patients major complications resulted in postoper-
ative death (postoperative mortality rate 5.4%). Both
patients developed liver failure and died in spite of maxi-
mum supportive therapy. The first patient had Child-Pugh
A cirrhosis as a result of hepatitis C and did not tolerate
resection of segment IV and RFA of 2 hepatocellular carci-
nomas in segments VII and VIII. Postoperatively she
developed an intrahepatic haematoma in the left lateral
liver lobe due to persisting bleeding from wound tissue.
This resulted in a hypovolumic shock requiring multiple
blood transfusions, and liver failure. She developed an
infected peritonitis (Staphylococcal aureus and Difteroids)
and underwent explorative laparotomy during which
necrotic liver parenchyma was resected. This did, how-
ever, not result in a clinical improvement and she eventu-
ally died due to fatal liver failure. The second patient, with
normal preoperative liver function, underwent right
hemihepatectomy with 9 colorectal metastases and RFA of
a metastasis with a diameter of 20 mm in segment II/III.
He was diagnosed with a liver abscess, liver failure and
Table 2: Indication for RFA in 37 combined partial liver 
resections and RFA in 35 patients
Tumour proximity to major vascular structures 13
Bilobular tumour distribution 12
Recurrence after surgical treatment 4
Extrahepatic disease 3
Inadequate functional hepatic reserve 3
Cirrhosis 2
Total 37
*Two patients were treated twice with RFA and partial liver resection
Table 1: Tumour histology in 37 combined partial liver 
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haematoma infected with Staphylococcal aureus and
Streptococcus was removed. Autopsy revealed that death
was due to septic shock secondary to necrotizing pancrea-
titis. In the middle hepatic vein partial thrombosis was
observed. This was not related to the RFA procedure, since
this metastasis was located deep in segment II/III. The
patient did not have portal vein thrombosis.
Median follow-up in the entire study group was 13
months (range 1–46). The estimated 1-, 2- and 3-year
overall survival rates were 84%, 70% and 43%, respec-
tively. Estimated disease-free 1-, 2- and 3-year survival
rates were 57%, 38% and 20%, respectively. Irradical
resection was observed in 5 patients. In 4 patients the
resection appeared irradical at histopathological examina-
tion, while in 1 patient optimal extrahepatic cytoreduc-
tion of stage IV ovarian carcinoma could not be achieved.
During follow-up local tumour progression was observed
in 10 RFA lesions (in 8 patients) as indicator of local treat-
ment failure, resulting in a local success rate of 88%. All
tumours were colorectal metastases. Four of these
tumours were larger than 3 cm. Four other tumours were
smaller, but were localized in the dome or centrally in the
liver (segment IVA, VI or VII). For the remaining 2
tumours no explanation for incomplete ablation could be
found. Median time to local tumour progression was 5
months. Seventeen patients (46%) developed hepatic
recurrence, while 15 patients (41%) developed extrahe-
patic disease. The median number of liver tumours treated
by local ablation per operation was 4 (range 2–10). In
patients with ≥ 4 tumours recurrence was 58%, while in
patients with < 4 tumours recurrence was 33%, respec-
tively (p = 0.12).
One single patient was treated for ovarian carcinoma stage
IV by multimodality therapy including chemotherapy
(Taxol), cytoreductive surgery and combined partial liver
resection and RFA. Optimal extrahepatic cytoreduction (<
1 cm residual disease) could not be achieved and after 4
months recurrence in the liver was observed. Two other
patients were also known to have extrahepatic disease
(table 2). In the first patient two colorectal lung metas-
tases were additionally removed. Three months after
resection and RFA hepatic recurrence was observed and
after 6 months local tumour progression and new extrahe-
patic lesions were diagnosed. The second patient under-
went an additional metastasectomy of an omental
metastasis of a Grawitz tumour. After 15 months of fol-
low-up the patient is still free of disease.
Discussion
Several series have been published on combined resection
and RFA [7,18-22]. However, all of these involved mono-
institutional experience of large cancer centres. We report
the results from a Dutch multi-institutional database,
involving 8 hospitals, including 1 cancer centre. Although
all resections and RFA procedures were performed by
experienced liver surgeons, this series may reflect daily
practice more accurately.
In the current series, we observed a morbidity rate of 32%
(major complication rate 16%) and a mortality rate of
5.4%. In the same period 87 patients were solely treated
by RFA in the hospitals involved in this study. In this
group the mortality rate after RFA was 0% and the RFA
Table 4: Twenty-four complications in 12 patients after 
combined partial liver resection and RFA
Major Number RFA related
Liver failure 3 0
Biliary stricture 3 3
Hepatic abscess 3 2
Peritoneal infection (S. Aureus) 2 0
Necrotising pancreatitis 1 0
Intrahepatic haematoma 1 0
Pulmonary embolus 1 0
Minor
Respiratory tract infection 2 0
Pleural effusion 2 0
Hepatic vein thrombosis 1 0
Hepatic artery damage 1 1
Cholangitis 1 0
Urine tract infection 1 0
Portal vein thrombosis 1 1
Wound infection 1 0
Total 24 7
*Two patients were treated twice with RFA and partial liver resection
Table 3: Largest resection in 37 patients treated with combined 
partial liver resection and RFA
Major resection
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versity Medical Centre Utrecht the mortality and morbid-
ity rate, following partial liver resection were 5.8% and
23% respectively. The 5-year survival rate after liver resec-
tion for colorectal metastases was 38%. [23]. Better figures
were reported by Pawlik et al, with a postoperative com-
plication rate of 19.8% and an overall mortality rate of
2.3% in 172 patients treated with partial liver resection
and RFA, among which 54% were major hepatectomies
[7], while numbers similar to ours were found by Mulier
et al, reporting a complication rate of 31.8 % and a mor-
tality rate of 4.5% in patients treated with open RFA in
combination with cryotherapy, partial hepatic resection
or extrahepatic resection [8]. Elias et al, did not observe
any postoperative deaths in 63 patients and found a mor-
bidity rate of 27% [21]. These series show that morbidity
and mortality rates of combined partial liver resection and
RFA are comparable with those of partial liver resection
alone [1-3].
In large series the 5-year survival is 36–39% after partial
liver resection alone as treatment for colorectal liver
metastasis, which is still considered the gold standard
[3,4,24]. Although few series have been published
describing long-term results after RFA, the results appear
promising. Solbiati et al, report a 3-year survival rate of
46% and Gillams et al, report a 5-year survival rate of 30%
[12,13,25]. Abdalla et al, compared RFA only, RFA + resec-
tion, resection only and chemotherapy retrospectively in
a large series (n = 418) [20]. They described that the com-
bination of partial liver resection and RFA in 101 patients
provided only modest survival benefit over chemotherapy
alone and was not different than following RFA only in
patients with colorectal liver metastases. Survival after
resection only was significantly better than all other treat-
ment modalities. In our series 3-year overall survival was
43%, while the disease-free survival was 20%. Due to the
number of patients with various diseases in our series,
conclusions with regard to oncological outcome cannot
be drawn from the present study.
Patient selection strongly improves the results in liver sur-
gery. Since substantial morbidity and mortality are intro-
duced, patients should be selected rigorously when
treated with combined resection and RFA. In our series, 1
patient died after right hepatectomy and controlateral RFA
of a colorectal metastasis measuring 20 mm. For patients
treated by combined major resection and RFA, percutane-
ous RFA combined with portal vein embolization fol-
lowed by hepatectomy one month later should ideally be
considered [26].
With regard to long term outcome the following aspects
should be taken into consideration. The total number of
tumours has been identified as a factor affecting time to
recurrence after resection alone [27-29] or combined
resection and RFA [7,20]. In this series, there was a trend
for an increased recurrence rate in patients treated for ≥ 4
tumours (p = 0.12). Since tumour diameter is also a risk
factor for local recurrence after RFA, only small tumours
should be treated by RFA when combined with resection
[12,30]. A cut off point of 30 mm diameter has been pro-
posed [21]. In general percutaneous RFA should not be
performed, since this approach results in increased local
recurrence [30]. A fourth risk factor affecting long term
survival is extrahepatic disease [28,31]. Although a 5-year
survival rate of 28% after "R0" resection of extrahepatic
disease in conjunction with partial hepatectomy for color-
ectal liver metastases has been published, this intended
"R0" resection could not be performed in 50% of oper-
ated patients [32]. Therefore, in our opinion extrahepatic
disease is a relative contraindication for combined resec-
tion and RFA. Only in patients with intraoperative poten-
tial for "R0" resection and simple extrahepatic disease
after meticulous exploration, combined resection and
RFA should be considered. We have treated only 3
patients with extrahepatic disease in our series with varia-
ble outcome. A fifth factor influencing survival might be
chemotherapy. Neoadjuvant chemotherapy allows 10–
15% of patients with unresectable colorectal liver metas-
tases to be rescued by liver surgery [33]. In a series of Elias,
et al the strategy of combined partial liver resection and
RFA with perioperative chemotherapy appeared favoura-
ble by doubling the median survival (from 18 to 36
months), when compared to similar unresectable colorec-
tal patients treated by chemotherapy alone [21]. RFA fol-
lowed by chemotherapy seems feasible, but no
randomised studies on its additive value are available at
present [21,34].
Conclusion
Combining partial liver resection and RFA augments the
number of patients who can be treated surgically. But this
strategy should only be performed following strict patient
selection and within the context of prospective clinical tri-
als.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
BF designed the study, carried out the data acquisition
and drafted the manuscript. MJ and FvD carried out the
data acquisition and participated in drafting and revising
the manuscript. RvH and TvG participated in the design of
the study and in drafting and revising the manuscript. IBR
conceived of the study and coordinated the draft and revi-
sion of the manuscript. All authors read and approved the
final manuscript.Page 5 of 6
(page number not for citation purposes)
World Journal of Surgical Oncology 2006, 4:46 http://www.wjso.com/content/4/1/46References
1. Belghiti J, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O:
Seven hundred forty-seven hepatectomies in the 1990s: an
update to evaluate the actual risk of liver resection.  J Am Coll
Surg 2000, 191:38-46.
2. Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S,
Corvera C, Weber S, Blumgart LH: Improvement in periopera-
tive outcome after hepatic resection: analysis of 1,803 con-
secutive cases over the past decade.  Ann Surg 2002,
236:397-407.
3. Ballantyne GH, Quin J: Surgical treatment of liver metastases in
patients with colorectal cancer.  Cancer 1993, 71:4252-4266.
4. Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG,
Marrero AM, Prasad M, Blumgart LH, Brennan MF: Liver resection
for colorectal metastases.  J Clin Oncol 1997, 15:938-946.
5. Elias D, Cavalcanti de Albuquerque A, Eggenspieler P, Plaud B,
Ducreux M, Spielmann M, Theodore C, Bonvalot S, Lasser P: Resec-
tion of liver metastases from a noncolorectal primary: indi-
cations and results based on 147 monocentric patients.  J Am
Coll Surg 1998, 187:487-493.
6. Elias D, Baton O, Sideris L, Matsuhisa T, Pocard M, Lasser P: Local
recurrences after intraoperative radiofrequency ablation of
liver metastases: a comparative study with anatomic and
wedge resections.  Ann Surg Oncol 2004, 11:500-505.
7. Pawlik TM, Izzo F, Cohen DS, Morris JS, Curley SA: Combined
resection and radiofrequency ablation for advanced hepatic
malignancies: results in 172 patients.  Ann Surg Oncol 2003,
10:1059-1069.
8. Mulier S, Mulier P, Ni Y, Miao Y, Dupas B, Marchal G, De Wever I,
Michel L: Complications of radiofrequency coagulation of liver
tumours.  Br J Surg 2002, 89:1206-1222.
9. Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg
SN: Treatment of focal liver tumors with percutaneous
radio-frequency ablation: complications encountered in a
multicenter study.  Radiology 2003, 226:441-451.
10. Curley SA, Marra P, Beaty K, Ellis LM, Vauthey JN, Abdalla EK, Scaife
C, Raut C, Wolff R, Choi H, Loyer E, Vallone P, Fiore F, Scordino F,
De Rosa V, Orlando R, Pignata S, Daniele B, Izzo F: Early and late
complications after radiofrequency ablation of malignant
liver tumors in 608 patients.  Ann Surg 2004, 239:450-458.
11. Jansen MC, van Duijnhoven FH, van Hillegersberg R, Rijken A, van
Coevorden F, van der Sijp J, Prevoo W, van Gulik TM: Adverse
effects of radiofrequency ablation of liver tumours in the
Netherlands.  Br J Surg 2005, 92:1248-1254.
12. Solbiati L, Livraghi T, Goldberg SN, Ierace T, Meloni F, Dellanoce M,
Cova L, Halpern EF, Gazelle GS: Percutaneous radio-frequency
ablation of hepatic metastases from colorectal cancer: long-
term results in 117 patients.  Radiology 2001, 221:159-166.
13. Livraghi T, Solbiati L, Meloni F, Ierace T, Goldberg SN, Gazelle GS:
Percutaneous radiofrequency ablation of liver metastases in
potential candidates for resection: the "test-of-time
approach".  Cancer 2003, 97:3027-3035.
14. Van Duijnhoven FH, Jansen MC, Junggeburt J, van Hillegersberg R,
Rijken A, van Coevorden F, van der Sijp JR, van Gulik TM, Slooter GD,
Klaase JM, Putter H, Tollenaar RA: Factors influencing local suc-
cess rate of radiofrequency ablation of colorectal liver
metastases.  Ann Surg Oncol  in press.
15. Curley SA, Izzo F, Delrio P, Ellis LM, Granchi J, Vallone P, Fiore F, Pig-
nata S, Daniele B, Cremona F: Radiofrequency ablation of unre-
sectable primary and metastatic hepatic malignancies:
results in 123 patients.  Ann Surg 1999, 230:1-8.
16. Goldberg SN, Charboneau JW, Dodd GD 3rd, Dupuy DE, Gervais
DA, Gillams AR, Kane RA, Lee FT Jr, Livraghi T, McGahan JP, Rhim H,
Silverman SG, Solbiati L, Vogl TJ, Wood BJ, International Working
Group on Image-Guided Tumor Ablation: International Working
Group on Image-Guided Tumor Ablation. Image-guided
tumor ablation: proposal for standardization of terms and
reporting criteria.  Radiology 2003, 228:335-345.
17. Balzan S, Belghiti J, Farges O, Ogata S, Sauvanet A, Delefosse D,
Durand F: The "50-50 criteria" on postoperative day 5: an
accurate predictor of liver failure and death after hepatec-
tomy.  Ann Surg 2005, 242:824-828.
18. Evrard S, Becouarn Y, Fonck M, Brunet R, Mathoulin-Pelissier S, Picot
V: Surgical treatment of liver metastases by radiofrequency
ablation, resection, or in combination.  Eur J Surg Oncol 2004,
30:399-406.
19. Elias D, Goharin A, El Otmany A, Taieb J, Duvillard P, Lasser P, de
Baere T: Usefulness of intraoperative radiofrequency thermo-
ablation of liver tumours associated or not with hepatec-
tomy.  Eur J Surg Oncol 2000, 26:763-769.
20. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess
K, Curley SA: Recurrence and outcomes following hepatic
resection, radiofrequency ablation, and combined resection/
ablation for colorectal liver metastases.  Ann Surg 2004,
239:818-825.
21. Elias D, Baton O, Sideris L, Boige V, Malka D, Liberale G, Pocard M,
Lasser P: Hepatectomy plus intraoperative radiofrequency
ablation and chemotherapy to treat technically unresectable
multiple colorectal liver metastases.  J Surg Oncol 2005,
90:36-42.
22. Navarra G, Ayav A, Weber JC, Jensen SL, Smadga C, Nicholls JP,
Habib NA, Jiao LR: Short- and-long term results of intraopera-
tive radiofrequency ablation of liver metastases.  Int J Colorectal
Dis 2005, 20:521-528.
23. Fioole B, Liem MS, Hennipman A, Borel Rinkes IH: Partial liver
resections: mortality, morbidity and risk factors for postop-
erative complications in 133 patients/137 operations;
Utrecht University Medical Center 1991/2000.  Ned Tijdschr
Geneeskd 2002, 146:210-213.
24. Scheele J, Stangl R, Altendorf-Hofmann A, Gall FP: Indicators of
prognosis after hepatic resection for colorectal secondaries.
Surgery 1991, 110:13-29.
25. Gillams AR, Lees WR: Radio-frequency ablation of colorectal
liver metastases in 167 patients.  Eur Radiol 2004, 14:2261-2267.
26. Elias D, Santoro R, Ouellet JF, Osmak L, de Baere T, Roche A: Simul-
taneous percutaneous right portal vein embolization and left
liver tumor radiofrequency ablation prior to a major right
hepatic resection for bilateral colorectal metastases.  Hepato-
gastroenterology 2004, 51:1788-1791.
27. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachel-
lier P, Jaeck D: Surgical resection of colorectal carcinoma
metastases to the liver. A prognostic scoring system to
improve case selection, based on 1568 patients. Association
Francaise de Chirurgie.  Cancer 1996, 77:1254-1262.
28. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH: Clinical score
for predicting recurrence after hepatic resection for meta-
static colorectal cancer: analysis of 1001 consecutive cases.
Ann Surg 1999, 230:309-318.
29. Sasaki A, Iwashita Y, Shibata K, Matsumoto T, Ohta M, Kitano S:
Analysis of Preoperative Prognostic Factors for Long-term
Survival After Hepatic Resection of Liver Metastasis of
Colorectal Carcinoma.  J Gastrointest Surg 2005, 9:374-380.
30. Mulier S, Ni Y, Jamart J, Ruers T, Marchal G, Michel L: Local recur-
rence after hepatic radiofrequency coagulation: multivariate
meta-analysis and review of contributing factors.  Ann Surg
2005, 242:158-171.
31. Iwatsuki S, Dvorchik I, Madariaga JR, Marsh JW, Dodson F, Bonham
AC, Geller DA, Gayowski TJ, Fung JJ, Starzl TE: Hepatic resection
for metastatic colorectal adenocarcinoma: a proposal of a
prognostic scoring system.  J Am Coll Surg 1999, 189:291-299.
32. Elias D, Sideris L, Pocard M, Ouellet JF, Boige V, Lasser P, Pignon JP,
Ducreux M: Results of R0 resection for colorectal liver metas-
tases associated with extrahepatic disease.  Ann Surg Oncol
2004, 11:274-280.
33. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giac-
chetti S, Paule B, Kunstlinger F, Ghemard O, Levi F, Bismuth H: Res-
cue surgery for unresectable colorectal liver metastases
downstaged by chemotherapy: a model to predict long-term
survival.  Ann Surg 2004, 240:644-657.
34. Scaife CL, Curley SA, Izzo F, Marra P, Delrio P, Daniele B, Cremona
F, Gershenwald JE, Chase JL, Lozano RD, Patt YZ, Fornage BD, Vau-
they JN, Woodall ML, Gonzalez KB, Ellis LM: Feasibility of adju-
vant hepatic arterial infusion of chemotherapy after
radiofrequency ablation with or without resection in
patients with hepatic metastases from colorectal cancer.
Ann Surg Oncol 2003, 10:348-354.Page 6 of 6
(page number not for citation purposes)
